title: Intensive care unit-related fluconazole use in Spain and Germany: patient characteristics and outcomes of a prospective multicenter longitudinal observational study.
abstract: BACKGROUND
  Candida spp. are a frequent cause of nosocomial bloodstream infections worldwide.
  
  
  OBJECTIVE
  To evaluate the use patterns and outcomes associated with intravenous (IV) fluconazole therapy in intensive care units in Spain and Germany.
  
  
  METHODS
  The research reported here was a prospective multicenter longitudinal observational study in adult intensive care unit patients receiving IV fluconazole. Demographic, microbiologic, therapy success, length of hospital stay, adverse event, and all-cause mortality data were collected at 14 sites in Spain and five in Germany, from February 2004 to November 2005.
  
  
  RESULTS
  Patients (n = 303) received prophylaxis (n = 29), empiric therapy (n = 140), preemptive therapy (n = 85), or definitive therapy (n = 49). A total of 298 patients (98.4%) were treated with IV fluconazole as first-line therapy. The treating physicians judged therapy successful in 66% of prophylactic, 55% of empiric, 45% of preemptive, and 43% of definitive group patients. In the subgroup of 152 patients with proven and specified Candida infection only, 32% suffered from Candida specified as potentially resistant to IV fluconazole. The overall mortality rate was 42%.
  
  
  CONCLUSIONS
  Our study informs treatment decision makers that approximately 32% of the patients with microbiological results available suffered from Candida specified as potentially resistant to IV fluconazole, highlighting the importance of appropriate therapy.
authors: Department of Anesthesiology, Intensive Care, and Pain Therapy, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany.
authors: Heimo
authors: H
authors: Wissing
authors: Jose
authors: J
authors: Ballus
authors: Tobias M
authors: TM
authors: Bingold
authors: Gonzalo
authors: G
authors: Nocea
authors: Karl J
authors: KJ
authors: Krobot
authors: Peter
authors: P
authors: Kaskel
authors: Ritesh N
authors: RN
authors: Kumar
authors: Panagiotis
authors: P
authors: Mavros
keywords: Candida; antifungal agents; fungal infection; therapy
references: J Infect Dis. 1993 Jul;168(1):195-201
references: 8515108
references: Intensive Care Med. 1997 Jan;23(1):23-30
references: 9037636
references: Clin Infect Dis. 2006 Jul 1;43(1):25-31
references: 16758414
references: J Antimicrob Chemother. 2007 Aug;60(2):424-8
references: 17562683
references: J Antimicrob Chemother. 2006 Mar;57(3):384-410
references: 16449304
references: Crit Care Med. 2011 Apr;39(4):665-70
references: 21169817
references: Clin Infect Dis. 2003 Jul 15;37(2):208-13
references: 12856213
references: Intensive Care Med. 1994 Aug;20(7):522-8
references: 7995872
references: Clin Infect Dis. 2006 Aug 15;43(4):e29-38
references: 16838223
references: Ann Intern Med. 2008 Jul 15;149(2):83-90
references: 18626047
references: Crit Care Med. 2005 Sep;33(9):1928-35; quiz 1936
references: 16148461
references: Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37
references: 23137135
references: Crit Care Med. 1999 Jun;27(6):1066-72
references: 10397206
references: Crit Care Med. 2006 Sep;34(9 Suppl):S215-24
references: 16917426
references: Clin Infect Dis. 2009 Mar 1;48(5):503-35
references: 19191635
references: Int J Antimicrob Agents. 2006 Jan;27(1):1-6
references: 16343859
references: Clin Microbiol Rev. 2007 Jan;20(1):133-63
references: 17223626
references: Clin Infect Dis. 2001 Jul 15;33(2):187-90
references: 11418878
references: Arch Surg. 1999 Jun;134(6):657-64; discussion 664-5
references: 10367877
references: Intensive Care Med. 2002 Dec;28(12):1708-17
references: 12447512
references: J Hosp Infect. 2004 May;57(1):8-13
references: 15142710
references: Clin Infect Dis. 2003 May 15;36(10):1221-8
references: 12746765
references: Crit Care Med. 2009 May;37(5):1612-8
references: 19325476
references: Intensive Care Med. 1998 Mar;24(3):206-16
references: 9565801
references: Eur J Med Res. 2002 May 31;7(5):183-91
references: 12069910
references: BMC Infect Dis. 2006 Feb 10;6:21
references: 16472387
references: Intensive Care Med. 2007 Oct;33(10):1679-81
references: 17646965
references: Am J Health Syst Pharm. 2002 Jan 1;59(1):33-41
references: 11813465
references: Crit Care Med. 2006 Mar;34(3):857-63
references: 16505666
references: Diagn Microbiol Infect Dis. 1999 Sep;35(1):19-25
references: 10529877
references: Ann Surg. 2001 Apr;233(4):542-8
references: 11303137
references: Antimicrob Agents Chemother. 2010 Aug;54(8):3149-54
references: 20498325
references: Adv Pharmacol. 1997;39:143-89
references: 9160115
references: Clin Infect Dis. 2005 Aug 1;41(3):301-7
references: 16007524
references: Clin Infect Dis. 2003 Sep 1;37(5):634-43
references: 12942393
references: Intensive Care Med. 2003 Jul;29(7):1069-76
references: 12756441
references: Crit Care Med. 1999 May;27(5):887-92
references: 10362409
references: J Hosp Infect. 1998 Mar;38(3):163-77
references: 9561467